SCHEMBL2374005

SCHEMBL2374005

Cn1cc(CC(C(=O)O)N(Cc2ccc(-c3ccccn3)cc2)C(=O)/C=C/c2ccc(C(F)(F)F)cc2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.37
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
TRPV1 Q8NER1 1/20 0.36
PPARD Q03181 2/20 0.35
PPARA Q07869 2/20 0.35
PPARG P37231 2/20 0.35
TRPM8 Q7Z2W7 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MITF O75030 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
KLF5 Q13887 1/20 0.35
HTR5A P47898 1/20 0.34
RORC P51449 1/20 0.34
EPHB4 P54760 1/20 0.34
TEK Q02763 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2374011 1.00 ESR1 (0.37) ESR1NOS3NOS1NOS2TRPV1
SCHEMBL2374704 0.92 NOS3 (0.42) ESR1NOS3NOS1NOS2TRPV1
SCHEMBL2374073 0.91 PPARG (0.39) ESR1NOS3NOS1NOS2PPARD
SCHEMBL2374076 0.91 PPARG (0.39) ESR1NOS3NOS1NOS2PPARD
SCHEMBL1124510 0.89 TRPV1 (0.42) NOS3NOS1NOS2TRPV1PPARG
SCHEMBL1124512 0.89 TRPV1 (0.42) NOS3NOS1NOS2TRPV1PPARG
SCHEMBL1124509 0.89 TRPV1 (0.42) NOS3NOS1NOS2TRPV1PPARG
SCHEMBL2374046 0.87 TRPM8 (0.37) NOS3NOS1NOS2TRPV1PPARD
SCHEMBL2374042 0.87 TRPM8 (0.37) NOS3NOS1NOS2TRPV1PPARD
SCHEMBL1359118 0.87 HPGD (0.37) KDM4EALDH1A1HPGDRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 ESR1 4676/4885NOS3 783/4885NOS1 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.